Compare MATW & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | ODTX |
|---|---|---|
| Founded | 1850 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 875.1M |
| IPO Year | 1995 | 2026 |
| Metric | MATW | ODTX |
|---|---|---|
| Price | $28.64 | $18.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 230.4K | ★ 246.6K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 59.07 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,795,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.95 | $15.10 |
| 52 Week High | $30.93 | $20.00 |
| Indicator | MATW | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 53.31 |
| Support Level | $25.33 | $15.10 |
| Resistance Level | $29.11 | $19.60 |
| Average True Range (ATR) | 0.78 | 1.32 |
| MACD | 0.08 | 0.16 |
| Stochastic Oscillator | 79.32 | 72.33 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.